Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Other(1)

Detailed Status

Completed3

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

unknown125%

completed375%

Recent Activity

0 active trials

Showing 4 of 4

unknownphase_1

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

NCT03750071

completedphase_1

VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

NCT02718430

completedphase_1

VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

NCT02718443

completedphase_1

VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

NCT01486329

Clinical Trials (4)

Showing 4 of 4 trials

NCT03750071Phase 1

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Unknown

NCT02718430Phase 1

VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

Completed

NCT02718443Phase 1

VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

Completed

NCT01486329Phase 1

VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4